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background: In Restless Legs Syndrome (RLS), nocturnal arterial blood pressure (BP) spikes are triggered by periodic leg movements during sleep 
(PLM), a key RLS symptom, and are identified as risk factors for increased cardiovascular morbidity and mortality. We tested whether dopamine 
agonist (rotigotine) therapy for idiopathic RLS can decrease the number of nocturnal BP elevations.
methods: This double-blind, placebo-controlled study (SP0977 ENCORE; NCT01455012) randomized patients 1:1 to rotigotine or placebo (1-3 
mg/24h dose titrated to RLS symptom relief) with continuous second by second BP and heart rate assessments performed during polysomnography 
at baseline and end of 4-week maintenance (EoM). The primary outcome was change from baseline to EoM in number of PLM-associated nocturnal 
systolic BP elevations (nSBP; defined as a ≥2.5 increase in linear regression slope for 5 consecutive heartbeats). Additional outcomes were the 
change from baseline to EoM in SBP and DBP elevation indices, and total PLM arousal episodes.
results: 81 patients (mean age: 57.2 [10.5] years; 63% female) were randomized to rotigotine (n=40) or placebo (n=41).
 
conclusions: This controlled study is the first to show that rotigotine reduced the number of PLM-associated nSBP elevations and other BP 
measures in patients with RLS. Whether this decrease in nocturnal BP will decrease cardiovascular risk in RLS patients, who are potentially at greater 
risk for these complications, requires further investigation.
